TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension
Stopped early · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Refractory Hypertension
In brief
A pilot study of subjects with refractory hypertension (on 3 concomitant agents with SBP \> 140 mmHg and a DBP \> 90 mmHg) randomized in a double-blind fashion to receive 4 single escalating doses of study medication in clinic.
Key facts
- Study ID
- NCT00899977
- Run by
- Targacept Inc.
- People needed
- 1
- Starts
- 2009-05-01
- Expected to finish
- 2009-12-01
- Last updated by the study team
- 2013-09-13
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Refractory hypertension, defined as a SBP of >140mmHg and a DBP > 90mmHg, on stable doses of at least 3 concomitant antihypertensive treatment (which must include a diuretic and an ACEI, ARB or RA) for 8 weeks prior to Screening. All approved antihypertensive treatments are allowed except for alpha-adrenergic blockers, hydralazine, clonidine, guanethidine, guanadrel, and rauwolfia alkaloids.
- Stable hypertension, as defined by: a. mean SBP on Day -7 that is within 20mmHg of the mean SBP on Day 1, with both mean SBPs > 140mmHg; and b. mean DBP on Day -7 that is within 10mm of the mean DBP on Day 1, with both mean DBPs > 90mmHg.
- Outpatient with stable housing.
- Subjects must be able to stay in the clinic for 8 hrs on Day 1, Day 8, Day 15, Day 22, and Day 36.
- Able to give and to sign informed consent.
You may not qualify if…
- Any unstable medical condition other than hypertension;
- Stage 3 hypertension (SBP > 180mmHg and/or DBP > 110mmHg);
- Heart rate > 100 beats per minute;
- WOCBP who is pregnant or who is planning to become pregnant during the study;
- History within past year of alcohol or illicit drug abuse;
- Unable to comply with study procedures in opinion of investigator;
- Concomitant medications for any medical condition that is uncontrolled for more than 2 weeks prior to study entry;
- Current use of alpha-adrenergic blocker, hydralazine, clonidine, guanethidine, guanadrel, or rauwolfia alkaloids;
- History of myocardial infarction or angina pectoris;
- Current seizure disorder;
- Renal insufficiency as defined by a serum creatinine > 2.0;
- Uncontrolled hypothyroidism, vitamin B12 or folic acid deficiency;
- History of or concurrent ileus, glaucoma, or urinary retention;
- Inability of subject to understand and sign the ICF;
- Known systemic infection (HBV, HCV, HIV, TB);
- Current use of smoking cessation therapy within 4 weeks of screening;
- Use of herbal supplements;
- Clinically significant finding on physical exam;
- Clinically significant laboratory or ECG abnormality, including QTcF > 460 msec;
- Participation in another clinical trial in last month;
- Body Mass Index (BMI) > 35.
- Body weight < 100 pounds.
- Site staff or family member of study site staff.
Where it is running
- Piedmont Medical Research — Winston-Salem, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.